Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
bullous pemphigoid
dupilumab
omalizumab
recalcitrant
treatment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
09
2020
accepted:
14
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
Identifiants
pubmed: 33584689
doi: 10.3389/fimmu.2020.611549
pmc: PMC7879677
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Omalizumab
2P471X1Z11
dupilumab
420K487FSG
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
611549Informations de copyright
Copyright © 2021 Seyed Jafari, Feldmeyer, Bossart, Simon, Schlapbach and Borradori.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunol Res. 2014 Aug;59(1-3):273-8
pubmed: 24845463
Dermatol Ther. 2019 Mar;32(2):e12829
pubmed: 30659716
Br J Dermatol. 2012 May;166(5):1140-2
pubmed: 22098309
J Invest Dermatol. 2001 Nov;117(5):1097-102
pubmed: 11710918
Front Immunol. 2019 Aug 14;10:1919
pubmed: 31474990
Clin Immunol. 2019 Jan;198:54-56
pubmed: 30557620
J Am Acad Dermatol. 2020 Jul;83(1):46-52
pubmed: 32179082
Dermatol Online J. 2019 Nov 15;25(11):
pubmed: 32045153
JAMA Dermatol. 2018 Oct 1;154(10):1225-1226
pubmed: 30140849
J Invest Dermatol. 2003 May;120(5):784-8
pubmed: 12713582
J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1778-1782
pubmed: 27357866
Dermatol Ther. 2020 Jan;33(1):e13190
pubmed: 31863534